Objective:

To discuss the impact of Sustained Virological Response (SVR) on the long-term prognosis of hepatocellular carcinoma (HCC) patients with concomitant hepatitis C virus (HCV) infection and to explore specific independent risk factors, such as tumor characteristics and patient demographics, affecting post-operative prognosis.

Key Findings:

• Patients achieving SVR had significantly improved post-operative survival rates compared to untreated patients, indicating a strong correlation.
• DAA treatment was associated with a significant reduction in tumor recurrence, highlighting its effectiveness.
• Independent risk factors for poor prognosis included larger tumor size and presence of microvascular invasion, which should be monitored closely.

Interpretation:

Achieving SVR through DAA therapy significantly enhances the prognosis of HCC patients with HCV, suggesting the importance of antiviral treatment in managing liver cancer outcomes, particularly in reducing recurrence rates.

Limitations:

• Retrospective design may introduce selection bias, potentially skewing results.
• Limited sample size may affect the generalizability of findings, necessitating further studies.
• Potential confounding factors not fully controlled due to retrospective nature, which could influence outcomes.

Conclusion:

DAA-induced SVR positively influences long-term outcomes in HCC patients with HCV, highlighting the need for integrated antiviral therapy in treatment protocols to improve patient survival and quality of life.